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Classification 
Note: Neoplasms of the vulva and vagina together 
account for less than 5% of all female genital tract 
cancers. Staging and grading of the lesions follows the 
TNM (Tumor, regional lymphoNode, Metastasis) and 
FIGO (International Federation of Gynecology and 
Obstetrics) recommendations. 
According to WHO recommendations, the main Vulva 
and Vagina categories are:  
VULVA NEOPLASIA:  
- I. Epithelial neoplasms 
    A. Squamous and related Tumors and precursors  
       1. Squamous cell carcinoma not otherwise 
specified  
       2. Basal cell carcinoma 
       3. Squamous intraepithelial neoplasia 
       4. Benign squamous lesions 
    B. Glandular Tumors 
       1. Paget disease 
       2. Bartholin gland Tumors: carcinomas, adenoma 
and adenomyoma  
       3. Tumor arising from specialized ano-genital 
mammary-like glands 
       4. Adenocarcinoma of Shene gland origin 
       5. Adenocarcinoma of other types 
       6. Adenoma of minor vestibular glands 
       7. Mixed Tumors of the vulva 
       8. Tumors of skin appendage origin 
- II. Soft tissue Tumors  
       1. Embryonal rhabdomyosarcoma (sarcoma 
botryoides)  
       2. Leiomyosarcoma 
       3. fibrous histiocytoma 
       4. Proximal epithelioid sarcoma 
       5. Alveolar soft part sarcoma 
       6. Liposarcoma 
       7. Dermatofibrosarcoma protuberans 
       8. Deep angiomyxoma 
       9. Superficial angiomyxoma  
       10. Angiomyofibroblastoma  
       11. Cellular angiofibroma 
       12. Leiomyoma  
       13. Granular cell Tumor  
       14. Other  
- III. Melanocytic Tumors  
       1. Malignant melanoma 
       2. Congenital melanocytic naevus  
       3. Acquired melanocytic naevus  
       4. Blue naevus  
       5. Atypical melanocytic naevus of genital type  
       6. Dysplastic melanocytic naevus  
- IV. Miscellaneous Tumors  
       1. Yolk sac Tumor 
       2. Merkel cell Tumor  
       3. Peripheral primitive neuroectodermal 
Tumor/Ewing sarcoma 
- V. Haematopoietic and lymphoid Tumors  
       1. Malignant lymphoma  
       2. Leukemia  
- VI. Secondary tumors 
VAGINA NEOPLASIA:  
- I. Epithelial neoplasms 
    A. Squamous Tumors and precursors  
       1. Squamous cell carcinoma not otherwise 
specified 
       2. Squamous intraepithelial neoplasia 
       3. Benign squamous lesions (condyloma 
acuminatum, squamous papilloma, fibroepithelial 
polyp)  
    B. Glandular lesions 
       1. Adenocarcinoma, NOS  
       2. Clear cell adenocarcinoma 
       3. Endometrioid adenocarcinoma 
       4. Mucinous adenocarcinoma 
       5. Mesonephric adenocarcinoma 
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       6. Mullerian papilloma 
       7. Adenoma not otherwise specified 
    C. Other epithelial Tumors 
       1. Adenosquamous carcinoma 
       2. Adenoid cystic carcinoma 
       3. Adenoid basal carcinoma 
       4. Carcinoid 
       5. Small cell carcinoma 
       6. Undifferentiated carcinoma 
- II. Mesenchymal Tumors  
       1. Sarcoma botryoides 
       2. Leiomyosarcoma 
       3. Endometrioid stromal sarcoma, low grade  
       4. Undifferentiated vaginal sarcoma  
       5. Alveolar soft part sarcoma 
       6. Leiomyoma  
       7. Deep angiomyxoma 
       8. Post-operative spindle nodule  
- III. Mixed epithelial and mesenchymal Tumors 
       1. Carcinosarcoma (Malignant Mullerian Mixed 
tumors; metaplastic carcinoma)  
       2. Adenosarcoma 
       3. Malignant mixed Tumors resembling synovial 
sarcoma 
       4. Benign mixed Tumors 
- IV. Melanocytic Tumors  
       1. Malignant melanoma  
       2. Blue naevus  
       3. Melanocytic naevus  
- V. Miscellaneous Tumors  
    A. Tumor of germ cell type  
       1. Yolk sac Tumor  
       2. Dermoid Cyst  
    B. Others  
       1. Peripheral primitive neuroectodermal 
Tumor/Ewing sarcoma  
       2. Adenomatoid Tumor  
       3. Malignant lymphoma  
       4. Granulocytic sarcoma  
- VI Secondary Tumors 
Clinics and pathology 
Disease  
Tumor of the vulva and vagina 
Note: Benign and malignant solid tumors at these sites 
are rare. The malignant lesions may have epithelial 
(squamous and glandular) and mesenchymal (soft 
tissue) origin. 
Etiology 
The high-risk (HR) human papillomaviruses (HPVs) 
infections have been identified as an essential although 
not sufficient factor in the pathogenesis of vulval and 
vagina carcinoma. It has been demonstrated that HPV
integration sites are distributed over the whole genome, 
with a preference for genomic fragile site. It has been 
also hypothesized that, at the early stages of infection, 
the virus genome, still in an not integrated state, 
expresses oncoproteins E6 and E7 which interfer with
the mechanisms of chromosome segregation during 
mitosis. This phenomenon, would favour the virus 
genome integration into chromosomal DNA. However, 
no evidence for targeted disruption of critical cellular 
genes by the integrated viral sequences has been found. 
According to this, two categories of affected patients 
can be distinguhished:  
Malignant lesions of the vulva  
Older age (mean 77): no vulva intraepithelial neoplasia 
(VIN) pre-existing pre-malignant condition, not Human 
Papilloma Virus (HPV) related, unknown etiology. 
Younger age (mean 55): usually associated with VIN, 
HPV-related (usually type 16). 
Malignant lesions of the vagina  
The strongest association is between squamous cell 
carcinoma and HPV types 16 and 18 infection. 
Association with a pre-malignant lesion, known as 
vaginal intraepithelial neoplasia (VAIN), was reported. 
Association with previous history of cervical 
intraepithelial neoplasia (CIN), invasive cervical 
carcinoma, or invasive vulvar carcinoma has been 
reported. 
Epidemiology 
Malignant neoplasms of the vulva together with 
neoplasms of the vagina account for less than 5% of all 
genital tract cancers. Squamous cell carcinoma 
(approximately 90% and 80% of the malignant 
neoplasms of the vulva and the vagina, respectively) is 
the most commonly found, and it is primarily a disea  
of elderly women, although it may be also observed in 
premenopausal women. Pigmented vulvar and vaginal 
lesions may occur, including nevi and melanoma, 
which accounts for 9% of vulvar and 5% of vaginal 
malignant lesions. Diethylstilbestrol (DES)-Associated 
Disease of the vagina are described: DES is a synthetic 
non-steroidal estrogen used in the early 1970s to 
prevent miscarriage. The female fetuses delivered by 
the mothers taking DES suffered from severe vaginal 
lesions including vaginal adenosis (benign) and clear 
cell adenocarcinoma. Malignant mesenchimal tumors 
of the vulva or vagina are rare: leiomyosarcoma is the 
most common vulvar lesion (mean age 35), 
dermatofibrosarcoma is one of the rarest: 25 cases 
reported, mean age 54. 
Clinics 
Cancer of the vulva and vagina at the very early stages 
tends to be asymptomatic. Delay in diagnosis is 
common, partially due to disease rarity and to delay in 
relating patient symptoms to the disease origin. 
Vulva. Major symptoms are: painless bleeding 
unrelated to the menstrual cycle, appearing of vulvar 
skin white and rough. 
Vagina. Major symptoms are painless vaginal bleeding 
(65-80% of all cases), difficult or painful urination, 
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pain in the pelvic area. Mainly post-menopausal 
women (70%) are affected. Many vulvar or vaginal 
growths are not neoplastic and may be treated by 
monitoring or simple excision. Suspicious growths 
require diagnostic biopsy and in case of cancer 
diagnosis surgical ablation is mandatory. 
Pathology 
The histopathology of vulva and vagina neoplasms 
reflects the different cell origins of the Tumors (see 
classification). Examples of both gross and microscopic 
images of these clinical entities can be viewed at 
http://www.gfmer.ch/selected_images_v2/level1.php?c
at1=8 & stype=n Immunohistochemical studies 
demonstrate that monoclonal antibodies to MIB-1 
(Ki67), a proliferation-associated marker, distinguish 
two different labeling patterns in the vulvar lesions : 
diffuse pattern, associated with poor prognosis, or 
localized pattern. 
Treatment 
Vulva. Small primary lesions less than 2 cm in 
diameter with superficial invasion are usually treaed 
with wide local excision with adequate surgical 
margins For tumors larger than 2 cm, or deeply 
growing into the underlying inguinal, 
lymphadenectomy is performed in order to plan a 
further partial or total vulvectomy. Radiation, with or 
without chemotherapy, may be used to treat advanced 
tumors or tumor recurrences, although there is not 
general consensus on the advantage of post-operative 
radiation therapy. 
Vagina. According to the FIGO, a vaginal lesion arises 
solely from the vagina : a vaginal lesion involving the 
external os of the cervix should be considered cervi al 
cancer, and a tumor involving both vulva and vagina 
should be considered vulvar cancer, and they should be 
treated as such. Radiotherapy is the most commonly 
used treatment for cancer of the vagina. Indication for 
diverse surgical interventions (radical hysterectomy, 
total or subtotal vaginectomy, vulvectomy, inguinal 
lymphadenectomy, etc), often accompained by 
radiation therapy, depends on the lesion type, stage, 
location, size and patient’s history. 
Prognosis 
Vulva. As with many other types of cancer prognosis 
depends on several factors, including the histological 
type of the lesion. In general, patients with increasing 
tumor stage have a lower rate of survival. The overall 
5-year survival rate ranges from 90% to 33%, 
depending upon whether and how many lymphonodes 
are involved (not in a directly proportional way). 
Recurrences are seen in a high percentage of patients 
within the first two years of follow-up. 
Vagina. The histologic type, size (Tumors less than 
4cm seem to be associated with a significantly better 
survival rate), stage and grade and location of the tumor 
influence the survival rate. The overall 5-year survival 




Data on cytogenetics of vulva and vagina cancer are 
scarse. Epithelial malignancy of both lesions show 
cytogenetic abnormalities, although no specific 
chromosome markers have been identified so far, and 
no consistent association between cytogenetic 
subgroups and histological differentiation have been 
observed. Complex karyotypes are frequent, however 
simple karyotypes have been observed in a number of 
cases as well. Cytogenetically unrelated clones, as well 
as closely related clones, were found in both in situ and 
infiltrating squamous cell carcinoma (SCC). Structural 
changes of chromosome 3, 8, 9, 11, 13, 14, 19 and 22 
have been frequently observed. Cytogenetically 
unrelated, abnormal clones, characterized by simple 
changes (chromosome X and 7 aneuploidy) have been 
described in Paget’s disease. The karyotypes of 
melanoma and dermatofibrosarcoma protuberans, 
arising in the vulva and/or vagina, substantially do not 
differ from the karyotypes of the same entities arising 
at other sites. A single case of vagina leiomyoma has
been reported recently and a t(7;8)(p13;q11.2) 
translocation without PLAG1 alteration has been 
described. 
Cytogenetics molecular 
Fluorescence in situ hybridization (FISH) supports the
cytogenetic pattern observed by conventional 
techniques, confirming the gain of chromosome 3q as 
an early and consistent change in carcinomas of the 
vulva, and the presence of EWS/FLI-1 fusion in 
extraosseous Ewing's sarcoma/peripheral 
neuroectodermal tumors of both vulva and vagina. 
CGH profiles are also confirmatory: chromosome 
imbalance with gains from the long arm of 
chromosome 3, 5, 8, 9 and losses from the 11q have 
been frequently observed. A comparison between 
papillomavirus-negative and papillomavirus-positive 
vulvar cancer indicated that chromosome 8q was more 
commonly gained in the positive cases. 
Genes involved and Proteins 
Note: No specific genes involved in vulva or vagina 
carcinogenesis have been found so far. An isolated 
study indicated a prominent role of the common IL1RN 
intron 2 polymorphism in vulvar carcinogenesis. 
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